PPP2R1A and neoplasm: We have further undertaken a reanalysis of the MSK-IMPACT cohort (including the clinical and genomic data of 1661 advanced cancer patients treated with ICB)36 and showed that PPP2R1A mutation (1.4%) was associated with an increased tumour mutation burden score and mutation count, and a better overall survival status (Supplementary Fig. 14a, b).